IMUNON reported a net loss of $14.5 million, or $6.83 per share, for the year ended December 31, 2025, an improvement from a net loss of $18.6 million, or $16.94 per share, in 2024. Operating expenses decreased by 23% to $14.7 million in 2025, with R&D expenses down 33% to $7.8 million and G&A expenses down 8% to $6.9 million. Final Phase 2 OVATION 2 Study data for IMNN-001 in advanced ovarian cancer showed a median 14.7-month increase in overall survival (45.1 vs. 30.4 months) for patients treated with IMNN-001 plus standard of care (SoC) chemotherapy. Women treated with IMNN-001, SoC chemotherapy, and PARP inhibitors achieved a median 24.2-month increase in overall survival (65.6 vs. 41.4 months). Enrollment in the pivotal Phase 3 OVATION 3 Study for IMNN-001 remains ahead of plan. The company completed a $7.0 million registered direct offering in December 2025, selling 1,939,114 shares (or pre-funded warrants) and warrants at a combined price of $3.61. Cash and cash equivalents stood at $8.8 million as of December 31, 2025, supported by $17.1 million in financing activities during the year. Proof-of-concept data for the PlaCCine DNA vaccine technology (IMNN-101) demonstrated safety, immunogenicity, and favorable storage stability, with the company seeking strategic partnerships for its development.